Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Neurocrine Biosciences, Inc. Post grant review
Case Number:
Case Type:
PGR
Status:
Terminated-Denied
Petitioner:
Neurocrine Biosciences, Inc.
-
November 27, 2024
PTAB Finds Hormone Treatment Patent Claims Invalid
The Patent Trial and Appeal Board has found Neurocrine Biosciences Inc. was able to show that all the claims in a patent owned by biotechnology company Spruce Biosciences Inc. relating to the treatment of a hormonal disorder were invalid.
-
December 05, 2023
PTAB To Eye Hormone Drug Again In Patent Fight
The Patent Trial and Appeal Board has agreed to look into whether various claims in a pair of patents owned by a biotechnology maker are invalid, the latest event in a larger intellectual property fight over a treatment for a hormonal disorder.
-
August 04, 2023
PTAB Has To Eye Hormone Drug Fight Again, Vidal Finds
The director of the U.S. Patent and Trademark Office on Friday reversed a Patent Trial and Appeal Board decision that refused to reassess a biotechnology maker's patent related to the treatment of a hormonal disorder.
-
July 25, 2023
Director Picks Up PTAB Denial Over Hormone Treatment
The director of the U.S. Patent and Trademark Office has agreed to review a Patent Trial and Appeal Board decision that refused to reassess a biotechnology maker's patent related to the treatment of a hormonal disorder.